Antimalarial drug resistance: linking Plasmodium falciparum parasite biology to the clinic.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 28777791.
- Also identified by DOI 10.1038/nm.4381 and PMC identifier 5747363.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The global adoption of artemisinin-based combination therapies (ACTs) in the early 2000s heralded a new era in effectively treating drug-resistant Plasmodium falciparum malaria. However, several Southeast Asian countries have now reported the emergence of parasites that have decreased susceptibility to artemisinin (ART) derivatives and ACT partner drugs, resulting in increasing rates of treatment failures. Here we review recent advances in understanding how antimalarials act and how resistance develops, and discuss new strategies for effectively combatting resistance, optimizing treatment and advancing the global campaign to eliminate malaria.
Medical subject headings
- Antimalarials
- Drug Resistance, Microbial
- Malaria, Falciparum
- Plasmodium falciparum